The unique dose of ‘Magic Mushrooms’ provides 5 years of relief of depression, researchers find
NEWNow you can listen to News articles!
Psilocybin, the main psychoactive ingredient in magical fungi, could relieve depression for at least five years after only one dose, according to a new study.
The research, presented on June 18 at the Psychdelic Science 2025 conference in Denver, followed by patients who had been diagnosed with clinical depression, also known as the major depressive disorder (MDD), and had participated in a previous study of psychocybin treatment in 2020.
“Most of the people who participated in our essay reported improvements in the intensity of depression symptoms or in the way they experienced depression in their life, lasting up to five years after the essay,” Digital Digital, co -author of the study, the author of the study study of the Center for Psychodelic Drug Research and Education Center at Ohio State University, told News Digital Digital.
Psychodelic as a potential mental health treatment are explored by the Trump administration
Doug Drysdale, CEO of the Canadian Pharmaceutical Company Cybin in Toronto, Ontario, told News Digital that the result speaks of the “exciting” potential of psilocybin and other psychedelic treatments in the treatment of MDD and other mental health conditions.
“The study results are certainly very encouraging,” said Drysdale, who did not participate in the study.
A worker has dry psychedelic fungi. The results of the new study are “certainly very encouraging,” said an executive of a pharmaceutical company. (James Macdonald/Bloomberg through Getty Images)
Previous studies pointed out the possibility of psilocybin as a potential antidepressant, which led researchers to carry out the first randomized clinical trial.
The initial 2020 essay, published in Jama Psychiatry, included 24 patients with major depressive disorder. Half received psilocybin at the beginning of the essay, and the other half received the treatment eight weeks later.
Each patient also underwent 11 hours of psychotherapy.
What is ketamine therapy? Mormon reality stars promotes a controversial treatment
A month after treatment, 17 patients reported having experienced symptoms. Fourteen of those who reported the complete remission of depression, according to the published study.
“The effectiveness of psilocybin therapy after only one or only a few administrations represents another substantial advantage over common use antidepressants that require daily administration,” the researchers wrote.
Patients seemed to respond much faster to psychedelic than traditional antidepressants, the researchers declared. (James Macdonald/Bloomberg through Getty Images)
The new study aimed to explore the longest effects of this treatment in 21 of the original trial participants.
The sixty -seven percent reported having been referring to depression five years after treatment, and also had less easily anxiety and daily functioning.
“The study does not explain the naturalistic changes that could have affected their depression in the five years after the main trial.”
For those whose depression returned, many still reported lasting benefits in their attitudes, perspectives and ability to pursue things that gave them meaning, Davis told News Digital.
“Certainly, a more controlled and rigorous study is required, but at least anecdotally, these findings are very interesting, and I am cautiously optimistic about the extended effectiveness potential provided by this type of treatments,” Drysdale added.
The sixty -seven percent of the participants reported having been in remission of depression five years after treatment, and also had less easily easier anxiety and functioning. (Jason Connolly/News through Getty Images)
Other factors may also have played a role in the long -term mental health benefits of participants, such as psychotherapy sessions or other antidepressants, experts agreed.
“The study does not take into account the naturalistic changes that could have affected their depression in the five years after the main trial, and the sample is not representative of the population of people suffering from depression,” Davis told News Digital.
Parkinson’s patients take ‘magical fungi’ see the key benefits, the study finds
Psilocybin has also been explored as a potential treatment for postpartum depression (PPD), which affects up to one in seven new mothers.
A 2022 study described the potential role of psychedelics in cases of PPD, discovering that it has been shown that psilocybin catalyzes a sensation of “reconnection” in new mothers.
Click here to register in our health newsletter
“This effect in PPD, by promoting a sense of ‘reconnection’ for the mother, can allow a better way of mood and maternal sensitivity towards the baby, which can positively affect the gratification of the maternal role and the mother-infant relationship,” said the researchers.
In February, Cleveland Clinic reported an upcoming study that explores the single dose psilocybin as a way of treating the PPD.
Psilocybin has been explored as a potential treatment for postpartum depression (PPD), which affects up to one in seven new mothers. (Istock)
The trial, now in its second phase, focuses on RE104, a patented medication similar to psilocybin.
Study participants will undergo multiple physical and mental health tests.
Risks and potential limitations
Ryan Moss, scientific director of Filament Health, a company for the development of natural psychedelic medications of the clinical stage in Canada, has emphasized the importance of administering psychedelics in a safe environment when dealing with mental health conditions.
For more health articles, visit www.Newsnews.com/health
“Psychedelic experiences can sometimes present anxiety, hallucinations and paranoia,” Moss told News Digital.
Experts recommend that the therapeutic use of psychedelic be carefully administered by medical experts.
“Some patients who use traditional psychedelic have informed having experienced adverse cardiovascular events during clinical trials.”
To mitigate these risks, the participants of the clinical trials recommended by MOSS receive exhaustive preparation and monitoring of trained professionals during the sessions.
Other factors may also have played a role in the long -term mental health benefits of the participants, said an expert (not in the photo), such as psychotherapy sessions or other antidepressants. (Istock)
Dr. Marc Siegel, Clinical Professor of Medicine at Nyu Langone Medical Center And the Senior Medical Analyst of News, previously interviewed two of the country’s main researchers about psychedelics: Dr. Rachel Yehuda, founder and director of the Center for Psychedelian Psychotherapy and Trauma Research in Mount Sinai in New York, and Dr. Charles Marmar, director of the PTSD Research Program in Nyu Langone.
Click here to get the News application
“They agree that there is a therapeutic potential if studied with great care under a very strict medical guide, but there is a great inconvenience in terms of unregulated recreational uses,” Siegel told News Digital at that time.
“Both doctors see a probable therapeutic value for psychedelics if they are carefully handled by Medical experts“Siegel added.
Melissa Rudy and Angelica Stabile, both of News Digital, contributed reports.
Khloe Quill is a lifestyle production assistant with News Digital. She and the lifestyle team cover a variety of stories issues that include food and drink, travel and health.